Find More Participants Faster
Bionymity provides Pharmaceuticals, clinical research organizations (CRO’s) and site management organizations (SMO’s) access to a rich database of de-identified clinical data. While de-identifying the clinical data, it also embeds a “re-identifier” to each message that can re-identify the patient only using the original Bionymity appliance. Bionymity enables companies to access mountains of clinical data and certain demographic data required for analyzing eligibility of patients for clinical trials.
Pharmaceutical companies, CROs and SMOs are able to more rapidly evaluate large populations of patients in search of qualified candidates. Once patients are identified, the system will provide the original provider with the re-identifier, minimizing the physician’s effort and increasing the quality of candidates for the trial.
Read Bionymity’s white paper on reducing recruitment time for clinical trials.
Early Detection = Faster Response
Bionymity can provide early detection of emerging infections within communities by aggregating clinical data from multiple providers in near real-time and providing analysis of this data to local, state and federal public health officials when results show that certain situations are outside of statistical norms.
This early warning system allows local public health stakeholders to implement action plans earlier, thus decreasing the severity of outbreaks and potentially controlling the spread of dangerous biological pathogens.
Mountains of Data for Researchers
For comparative efficacy research, Bionymity can provide access to the de-identified clinical records of patients. Furthermore, with additional data coming in every second of every day, Bionymity can provide researchers with the ability to “follow” an unidentified patient so that the researcher always has an up-to-the-minute profile for that patient.